{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:37:06Z","timestamp":1777289826948,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40272-025-00733-2","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T14:33:21Z","timestamp":1773412401000},"page":"295-305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fixed Dosing of Leuprolide Acetate, a GnRH Agonist, in Children with Central Precocious Puberty: A Population Pharmacokinetic Justification"],"prefix":"10.1007","volume":"28","clinical-trial-number":[{"clinical-trial-number":"nct00635817","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7307-9851","authenticated-orcid":false,"given":"Chay Ngee","family":"Lim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2069-8472","authenticated-orcid":false,"given":"Omar N.","family":"Al Yacoub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3065-768X","authenticated-orcid":false,"given":"Nael M.","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9261-1583","authenticated-orcid":false,"given":"Ahmed Hamed","family":"Salem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"733_CR1","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1210\/jc.2013-1024","volume":"98","author":"JS Fuqua","year":"2013","unstructured":"Fuqua JS. Treatment and outcomes of precocious puberty: an update. J Clin Endocrinol Metab. 2013;98:2198\u2013207.","journal-title":"J Clin Endocrinol Metab"},{"key":"733_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.5152\/tpa.2015.2281","volume":"50","author":"G Catli","year":"2015","unstructured":"Catli G, Erdem P, Anik A, Abaci A, Bober E. Clinical and laboratory findings in the differential diagnosis of central precocious puberty and premature thelarche. T\u00fcrk Pediatr Ar\u015fivi. 2015;50:20\u20136.","journal-title":"T\u00fcrk Pediatr Ar\u015fivi."},{"key":"733_CR3","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-1783","volume":"123","author":"J-C Carel","year":"2009","unstructured":"Carel J-C, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, Group E-LGACC, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009;123:e752\u201362.","journal-title":"Pediatrics"},{"key":"733_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141844","volume":"10","author":"SH Kim","year":"2015","unstructured":"Kim SH, Huh K, Won S, Lee K-W, Park M-J. A significant increase in the incidence of central precocious puberty among Korean girls from 2004 to 2010. PLoS ONE. 2015;10:e0141844.","journal-title":"PLoS ONE"},{"key":"733_CR5","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1210\/jc.2010-1025","volume":"95","author":"L Soriano-Guill\u00e9n","year":"2010","unstructured":"Soriano-Guill\u00e9n L, Corripio R, Labarta JI, Ca\u00f1ete R, Castro-Feij\u00f3o L, Espino R, et al. Central precocious puberty in children living in Spain: incidence, prevalence, and influence of adoption and immigration. J Clin Endocrinol Metab. 2010;95:4305\u201313.","journal-title":"J Clin Endocrinol Metab"},{"key":"733_CR6","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1542\/peds.2005-0012","volume":"116","author":"G Teilmann","year":"2005","unstructured":"Teilmann G, Pedersen CB, Jensen TK, Skakkeb\u00e6k NE, Juul A. Prevalence and incidence of precocious pubertal development in Denmark: an epidemiologic study based on national registries. Pediatrics. 2005;116:1323\u20138.","journal-title":"Pediatrics"},{"key":"733_CR7","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s12902-025-02084-y","volume":"25","author":"Y Chen","year":"2025","unstructured":"Chen Y, Tang J, Huang S, Chen Y, Kong H, Lin C, et al. The incidence of early and precocious puberty of children in two Chinese cities: a multi-center prospective cohort study. BMC Endocr Disord. 2025;25:256.","journal-title":"BMC Endocr Disord"},{"key":"733_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1210\/jcem.84.2.5431","volume":"84","author":"AM Pasquino","year":"1999","unstructured":"Pasquino AM, Pucarelli I, Segni M, Matrunola M, Cerroni F, Cerrone F. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone. J Clin Endocrinol Metab. 1999;84:449\u201352.","journal-title":"J Clin Endocrinol Metab"},{"key":"733_CR9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2165\/00003088-200241070-00003","volume":"41","author":"P Periti","year":"2002","unstructured":"Periti P, Mazzei T, Mini E. Clinical pharmacokinetics of depot leuprorelin. Clin Pharmacokinet. 2002;41:485\u2013504.","journal-title":"Clin Pharmacokinet"},{"key":"733_CR10","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/jps.2600750211","volume":"75","author":"LT Sennello","year":"1986","unstructured":"Sennello LT, Finley RA, Chu S, Jagst C, Max D, Rollins DE, et al. Single\u2010dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration. J Pharm Sci. 1986;75:158\u201360.","journal-title":"J Pharm Sci"},{"key":"733_CR11","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1210\/jc.2011-2704","volume":"97","author":"PA Lee","year":"2012","unstructured":"Lee PA, Klein K, Mauras N, Neely EK, Bloch CA, Larsen L, et al. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. J Clin Endocrinol Metab. 2012;97:1572\u201380.","journal-title":"J Clin Endocrinol Metab"},{"key":"733_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1687-9856-2011-7","volume":"2011","author":"PA Lee","year":"2011","unstructured":"Lee PA, Neely EK, Fuqua J, Yang D, Larsen LM, Mattia-Goldberg C, et al. Efficacy of leuprolide acetate 1-month depot for central precocious puberty (CPP): growth outcomes during a prospective, longitudinal study. Int J Pediatr Endocrinol. 2011;2011:7\u20137.","journal-title":"Int J Pediatr Endocrinol"},{"key":"733_CR13","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40261-014-0193-2","volume":"34","author":"NM Mostafa","year":"2014","unstructured":"Mostafa NM, Hosmane B, Larsen LM, Chwalisz K, Chiu Y-L, Pradhan RS. Pharmacokinetic and exposure\u2013response analyses of leuprolide following administration of leuprolide acetate 3-month depot formulations to children with central precocious puberty. Clin Drug Investig. 2014;34:441\u20138.","journal-title":"Clin Drug Investig"},{"key":"733_CR14","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481\u2013504.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"733_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143\u201351.","journal-title":"AAPS J"},{"key":"733_CR16","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1023\/A:1015818504906","volume":"8","author":"H Okada","year":"1991","unstructured":"Okada H, Inoue Y, Heya T, Ueno H, Ogawa Y, Toguchi H. Pharmacokinetics of once-a-month injectable microspheres of leuprolide acetate. Pharm Res. 1991;8:787\u201391.","journal-title":"Pharm Res"},{"key":"733_CR17","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1023\/A:1018936815654","volume":"11","author":"H Okada","year":"1994","unstructured":"Okada H, Doken Y, Ogawa Y, Toguchi H. Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers. Pharm Res. 1994;11:1143\u20137.","journal-title":"Pharm Res"},{"key":"733_CR18","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","volume":"34","author":"RM Savic","year":"2007","unstructured":"Savic RM, Jonker DM, Kerbusch T, Karlsson MO. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007;34:711\u201326.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"733_CR19","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1128\/AAC.00461-07","volume":"52","author":"JJ Wilkins","year":"2008","unstructured":"Wilkins JJ, Savic RM, Karlsson MO, Langdon G, McIlleron H, Pillai G, et al. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob Agents Chemother. 2008;52:2138\u201348.","journal-title":"Antimicrob Agents Chemother"},{"key":"733_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31\u201341.","journal-title":"Nephron"},{"key":"733_CR21","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","volume":"317","author":"RD Mosteller","year":"1987","unstructured":"Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098\u20131098.","journal-title":"N Engl J Med"},{"key":"733_CR22","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11:558\u201369.","journal-title":"AAPS J"},{"key":"733_CR23","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s40262-015-0251-9","volume":"54","author":"CN Lim","year":"2015","unstructured":"Lim CN, Salem AH. A semi-mechanistic integrated pharmacokinetic\/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients. Clin Pharmacokinet. 2015;54:963\u201373.","journal-title":"Clin Pharmacokinet"},{"key":"733_CR24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2147\/CIA.S27931","volume":"8","author":"UW Tunn","year":"2013","unstructured":"Tunn UW, Gruca D, Bacher P. Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation. Clin Interv Aging. 2013;8:457\u201364.","journal-title":"Clin Interv Aging"},{"key":"733_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000056540","volume":"60","author":"UW Tunn","year":"1998","unstructured":"Tunn UW, Bargelloni U, Cosciani S, Fiaccavento G, Guazzieri S, Pagano F. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer. Urol Int. 1998;60:9\u201317.","journal-title":"Urol Int"},{"key":"733_CR26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/03000605900180S108","volume":"18","author":"T Mazzei","year":"1990","unstructured":"Mazzei T, Mini E, Rizzo M, Periti P. Human pharmacokinetic and pharmacodynamic profiles of leuprorelin acetate depot in prostatic cancer patients. J Int Med Res. 1990;18:42\u201356.","journal-title":"J Int Med Res"},{"key":"733_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1159\/000030200","volume":"60","author":"MS Khan","year":"1998","unstructured":"Khan MS, O\u2019Brien A. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-Depot in patients with advanced and metastatic carcinoma of the prostate. Urol Int. 1998;60:33\u201340.","journal-title":"Urol Int"},{"key":"733_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0169-409X(97)00050-1","volume":"28","author":"H Okada","year":"1997","unstructured":"Okada H. One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv Drug Deliv Rev. 1997;28:43\u201370.","journal-title":"Adv Drug Deliv Rev"},{"key":"733_CR29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/pr.2014.143","volume":"77","author":"LC Ku","year":"2015","unstructured":"Ku LC, Smith PB. Dosing in neonates: special considerations in physiology and trial design. Pediatr Res. 2015;77:2\u20139.","journal-title":"Pediatr Res"},{"key":"733_CR30","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1517\/17425255.3.5.733","volume":"3","author":"C Tom-Revzon","year":"2007","unstructured":"Tom-Revzon C. Erratic absorption of intramuscular antimicrobial delivery in infants and children. Expert Opin Drug Metab Toxicol. 2007;3:733\u201340.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"733_CR31","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra035092","volume":"349","author":"AJJ Wood","year":"2003","unstructured":"Wood AJJ, Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, et al. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157\u201367.","journal-title":"N Engl J Med"},{"key":"733_CR32","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1056\/NEJM197609022951006","volume":"295","author":"J Koch-Weser","year":"1976","unstructured":"Koch-Weser J, Greenblatt DJ. Intramuscular injection of drugs. N Engl J Med. 1976;295:542\u20136.","journal-title":"N Engl J Med"},{"key":"733_CR33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1208\/s12248-012-9320-2","volume":"14","author":"M Joerger","year":"2012","unstructured":"Joerger M. Covariate pharmacokinetic model building in oncology and its potential clinical relevance. AAPS J. 2012;14:119\u201332.","journal-title":"AAPS J"},{"key":"733_CR34","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/247386","volume":"2015","author":"HNP Kendirci","year":"2015","unstructured":"Kendirci HNP, A\u011flad\u0131o\u011flu SY, Ba\u015f VN, \u00d6nder A, \u00c7etinkaya S, Aycan Z. Evaluating the efficacy of treatment with a GnRH analogue in patients with central precocious puberty. Int J Endocrinol. 2015;2015:247386.","journal-title":"Int J Endocrinol"},{"key":"733_CR35","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2165\/11596370-000000000-00000","volume":"51","author":"S Bai","year":"2012","unstructured":"Bai S, Jorga K, Xin Y, Jin D, Zheng Y, Damico-Beyer LA, et al. A guide to rational dosing of monoclonal antibodies. Clin Pharmacokinet. 2012;51:119\u201335.","journal-title":"Clin Pharmacokinet"},{"key":"733_CR36","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s40262-013-0085-2","volume":"52","author":"R Narwal","year":"2013","unstructured":"Narwal R, Roskos LK, Robbie GJ. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-\u03b1 monoclonal antibody, in systemic lupus erythematosus. Clin Pharmacokinet. 2013;52:1017\u201327.","journal-title":"Clin Pharmacokinet"},{"key":"733_CR37","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3390\/pharmaceutics2040389","volume":"2","author":"R Shi","year":"2010","unstructured":"Shi R, Derendorf H. Pediatric dosing and body size in biotherapeutics. Pharmaceutics. 2010;2:389\u2013418.","journal-title":"Pharmaceutics"},{"key":"733_CR38","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1177\/0091270009337512","volume":"49","author":"DD Wang","year":"2009","unstructured":"Wang DD, Zhang S, Zhao H, Men AY, Parivar K. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol. 2009;49:1012\u201324.","journal-title":"J Clin Pharmacol"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00733-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-025-00733-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00733-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T10:48:50Z","timestamp":1777286930000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-025-00733-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["733"],"URL":"https:\/\/doi.org\/10.1007\/s40272-025-00733-2","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Omar N. Al Yacoub, Ahmed H. Salem, and Nael M. Mostafa are employees of AbbVie and may hold AbbVie stock or options. Chay Ngee Lim is a former employee of AbbVie and may hold stock in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study reported herein was conducted in accordance with the International Council for Harmonisation guidelines, applicable regulations, and guidelines governing clinical study conduct and the ethical principles that have their origin in the Declaration of Helsinki. Approval was granted by institutional review boards and independent ethics committees at participating institutions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients signed an informed consent form regarding publishing their data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis data sets), as well as other information (e.g., protocols, clinical study reports, or analysis plans), provided the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. These clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following the review and approval of a research proposal and a statistical analysis plan, and the execution of a data sharing agreement. Data requests can be submitted at any time after approval in the USA and Europe and after acceptance of this manuscript for publication. The data will be accessible for 12 months, with possible extensions considered. For more information on the process or to submit a request, visit the following link:\n                      \n                      then select \u201cHome\u201d.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design. Data collection and analysis were performed by CL, OA, AS, and NM. The first draft of the manuscript was written by CL and OA and all authors critically reviewedprevious versions of the manuscript. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}